ALT Stock Overview
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Altimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.00 |
| 52 Week High | US$14.84 |
| 52 Week Low | US$2.09 |
| Beta | 0.074 |
| 11 Month Change | 2.04% |
| 3 Month Change | 9.63% |
| 1 Year Change | 177.78% |
| 33 Year Change | -45.14% |
| 5 Year Change | 270.37% |
| Change since IPO | -97.05% |
Recent News & Updates
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Sep 21We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Sep 12
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Aug 27Recent updates
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Sep 21We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Sep 12Altimmune: Emerging Position In Competitive Space, But Risks Remain
Aug 27Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
Jun 24Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
May 27Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns
Sep 17We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely
Aug 06Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Jul 27Shareholder Returns
| ALT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.8% | -3.3% | 1.9% |
| 1Y | 177.8% | 18.7% | 32.8% |
Return vs Industry: ALT exceeded the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: ALT exceeded the US Market which returned 32.8% over the past year.
Price Volatility
| ALT volatility | |
|---|---|
| ALT Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALT has not had significant price volatility in the past 3 months.
Volatility Over Time: ALT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 59 | Vipin Garg | altimmune.com |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune, Inc. Fundamentals Summary
| ALT fundamental statistics | |
|---|---|
| Market cap | US$506.03m |
| Earnings (TTM) | -US$101.35m |
| Revenue (TTM) | US$409.00k |
1,216x
P/S Ratio-4.9x
P/E RatioIs ALT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALT income statement (TTM) | |
|---|---|
| Revenue | US$409.00k |
| Cost of Revenue | US$77.94m |
| Gross Profit | -US$77.53m |
| Other Expenses | US$23.82m |
| Earnings | -US$101.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | -18,955.99% |
| Net Profit Margin | -24,778.97% |
| Debt/Equity Ratio | 0% |
How did ALT perform over the long term?
See historical performance and comparison